Valentina Mercurio

List of Publications by Citations

Source: https://exaly.com/author-pdf/6916339/valentina-mercurio-publications-by-citations.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

65 1,014 17 30 h-index g-index papers citations 80 1,454 5.1 4.32 L-index avg, IF ext. citations ext. papers

| # | Paper | IF | Citations |
|----|--|------|-----------|
| 65 | Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis. <i>European Heart Journal</i> , 2020 , 41, 1733-1743 | 9.5 | 114 |
| 64 | Antineoplastic Drug-Induced Cardiotoxicity: A Redox Perspective. Frontiers in Physiology, 2018, 9, 167 | 4.6 | 74 |
| 63 | Immune Checkpoint Inhibitors and Cardiac Toxicity: An Emerging Issue. <i>Current Medicinal Chemistry</i> , 2018 , 25, 1327-1339 | 4.3 | 69 |
| 62 | Cardiovascular and metabolic effects of Berberine. World Journal of Cardiology, 2010, 2, 71-7 | 2.1 | 64 |
| 61 | A nutraceutical combination improves insulin sensitivity in patients with metabolic syndrome. <i>World Journal of Cardiology</i> , 2012 , 4, 77-83 | 2.1 | 54 |
| 60 | The novel butyrate derivative phenylalanine-butyramide protects from doxorubicin-induced cardiotoxicity. <i>European Journal of Heart Failure</i> , 2019 , 21, 519-528 | 12.3 | 45 |
| 59 | Influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors 2019 , 7, 53 | | 42 |
| 58 | Models of Heart Failure Based on the Cardiotoxicity of Anticancer Drugs. <i>Journal of Cardiac Failure</i> , 2016 , 22, 449-58 | 3.3 | 42 |
| 57 | Serum soluble ST2 and interleukin-33 levels in patients with pulmonary arterial hypertension. <i>International Journal of Cardiology</i> , 2013 , 168, 1545-7 | 3.2 | 41 |
| 56 | Sex-related differences in COVID-19 lethality. British Journal of Pharmacology, 2020, 177, 4375-4385 | 8.6 | 36 |
| 55 | Heart Failure and Cancer: Mechanisms of Old and New Cardiotoxic Drugs in Cancer Patients. <i>Cardiac Failure Review</i> , 2019 , 5, 112-118 | 4.2 | 27 |
| 54 | Right ventricular longitudinal strain is diminished in systemic sclerosis compared with idiopathic pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2017 , 50, | 13.6 | 25 |
| 53 | Improvement in Right Ventricular Strain with Ambrisentan and Tadalafil Upfront Therapy in Scleroderma-associated Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018 , 197, 388-391 | 10.2 | 24 |
| 52 | Poor survival in patients with scleroderma and pulmonary hypertension due to heart failure with preserved ejection fraction. <i>Pulmonary Circulation</i> , 2017 , 7, 409-420 | 2.7 | 21 |
| 51 | Pulmonary arterial hypertension and atrial arrhythmias: incidence, risk factors, and clinical impact. <i>Pulmonary Circulation</i> , 2018 , 8, 2045894018769874 | 2.7 | 20 |
| 50 | Insulin resistance: Is it time for primary prevention?. World Journal of Cardiology, 2012, 4, 1-7 | 2.1 | 19 |
| 49 | Preventing antiblastic drug-related cardiomyopathy: old and new therapeutic strategies. <i>Journal of Cardiovascular Medicine</i> , 2016 , 17 Suppl 1, S64-75 | 1.9 | 18 |

(2020-2020)

| 48 | Comorbidities in chronic heart failure: An update from Italian Society of Cardiology (SIC) Working Group on Heart Failure. <i>European Journal of Internal Medicine</i> , 2020 , 71, 23-31 | 3.9 | 17 |
|----|---|---------------------------|------------|
| 47 | Risk assessment in scleroderma patients with newly diagnosed pulmonary arterial hypertension: application of the ESC/ERS risk prediction model. <i>European Respiratory Journal</i> , 2018 , 52, | 13.6 | 17 |
| 46 | Inflammatory, Serological and Vascular Determinants of Cardiovascular Disease in Systemic Lupus Erythematosus Patients. <i>International Journal of Molecular Sciences</i> , 2019 , 20, | 6.3 | 16 |
| 45 | Sacubitril/valsartan in patients listed for heart transplantation: effect on physical frailty. <i>ESC Heart Failure</i> , 2020 , 7, 757-762 | 3.7 | 16 |
| 44 | Lung ultrasound as diagnostic tool for SARS-CoV-2 infection. <i>Internal and Emergency Medicine</i> , 2021 , 16, 471-476 | 3.7 | 16 |
| 43 | A comprehensive echocardiographic method for risk stratification in pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2020 , 56, | 13.6 | 14 |
| 42 | Response to pulmonary vasodilator treatment in a former smoker with combined interstitial lung disease complicated by pulmonary hypertension: case report and review of the literature. <i>Heart and Lung: Journal of Acute and Critical Care</i> , 2012 , 41, 512-7 | 2.6 | 12 |
| 41 | Risk Reduction and Hemodynamics with Initial Combination Therapy in Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021 , 203, 484-492 | 10.2 | 12 |
| 40 | What Is the Cardiac Impact of Chemotherapy and Subsequent Radiotherapy in Lymphoma Patients?. <i>Antioxidants and Redox Signaling</i> , 2019 , 31, 1166-1174 | 8.4 | 11 |
| 39 | New Drugs, Therapeutic Strategies, and Future Direction for the Treatment of Pulmonary Arterial Hypertension. <i>Current Medicinal Chemistry</i> , 2019 , 26, 2844-2864 | 4.3 | 11 |
| 38 | Progress in Understanding, Diagnosing, and Managing Cardiac Complications of Systemic Sclerosis. <i>Current Rheumatology Reports</i> , 2019 , 21, 68 | 4.9 | 11 |
| 37 | Cardiovascular Toxicity of Immune Checkpoint Inhibitors: Clinical Risk Factors. <i>Current Oncology Reports</i> , 2021 , 23, 13 | 6.3 | 11 |
| 36 | Ticagrelor Conditioning Effects Are Not Additive to Cardioprotection Induced by Direct NLRP3 Inflammasome Inhibition: Role of RISK, NLRP3, and Redox Cascades. <i>Oxidative Medicine and Cellular Longevity</i> , 2020 , 2020, 9219825 | 6.7 | 10 |
| 35 | Pharmacovigilating cardiotoxicity of immune checkpoint inhibitors. <i>Lancet Oncology, The</i> , 2018 , 19, 15 | 45 <u>2</u> 1 <i>5</i> 40 | 6 9 |
| 34 | Pulmonary Hypertension Phenotypes in Systemic Sclerosis: The Right Diagnosis for the Right Treatment. <i>International Journal of Molecular Sciences</i> , 2020 , 21, | 6.3 | 8 |
| 33 | EXPRESS: Cardiac Sympathetic Dysfunction in Pulmonary Arterial Hypertension: Lesson from Left-sided Heart Failure. <i>Pulmonary Circulation</i> , 2019 , 2045894019868620 | 2.7 | 8 |
| 32 | Efficacy of a nutraceutical combination on lipid metabolism in patients with metabolic syndrome: a multicenter, double blind, randomized, placebo controlled trial. <i>Lipids in Health and Disease</i> , 2019 , 18, 66 | 4.4 | 7 |
| 31 | Effect of Sacubitril-Valsartan in reducing depression in patients with advanced heart failure. Journal of Affective Disorders, 2020, 272, 132-137 | 6.6 | 7 |

| 30 | Redox Imbalances in Ageing and Metabolic Alterations: Implications in Cancer and Cardiac Diseases. An Overview from the Working Group of Cardiotoxicity and Cardioprotection of the Italian Society of Cardiology (SIC). <i>Antioxidants</i> , 2020 , 9, | 7.1 | 7 |
|----|---|-----|---|
| 29 | Metabolomic Perspectives in Antiblastic Cardiotoxicity and Cardioprotection. <i>International Journal of Molecular Sciences</i> , 2019 , 20, | 6.3 | 6 |
| 28 | A nutraceutical combination reduces left ventricular mass in subjects with metabolic syndrome and left ventricular hypertrophy: A multicenter, randomized, double-blind, placebo-controlled trial. <i>Clinical Nutrition</i> , 2020 , 39, 1379-1384 | 5.9 | 6 |
| 27 | Cancer Risk in the Heart Failure Population: Epidemiology, Mechanisms, and Clinical Implications. <i>Current Oncology Reports</i> , 2020 , 23, 7 | 6.3 | 6 |
| 26 | How can we manage the cardiac toxicity of immune checkpoint inhibitors?. <i>Expert Opinion on Drug Safety</i> , 2021 , 20, 685-694 | 4.1 | 5 |
| 25 | Time-weighted lactate as a predictor of adverse outcome in acute heart failure. <i>ESC Heart Failure</i> , 2021 , 8, 539-545 | 3.7 | 4 |
| 24 | Right heart dysfunction: from pathophysiologic insights to therapeutic options: a translational overview. <i>Journal of Cardiovascular Medicine</i> , 2018 , 19, 613-623 | 1.9 | 4 |
| 23 | Effects of a nutraceutical combination on left ventricular remodeling and vasoreactivity in subjects with the metabolic syndrome. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2012 , 22, e13-4 | 4.5 | 3 |
| 22 | Hemodynamics and risk assessment 2 years after the initiation of upfront ambrisentan-tadalafil in pulmonary arterial hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2020 , 39, 1389-1397 | 5.8 | 3 |
| 21 | Assessment of right ventricular reserve utilizing exercise provocation in systemic sclerosis. <i>International Journal of Cardiovascular Imaging</i> , 2021 , 37, 2137-2147 | 2.5 | 3 |
| 20 | Sex-Related Differences in COVID-19 Lethality | | 2 |
| 19 | The use of chest ultrasonography in suspected cases of COVID-19 in the emergency department. <i>Future Science OA</i> , 2020 , 7, FSO635 | 2.7 | 2 |
| 18 | Efficacy and safety of valsartan plus hydroclorothiazide for high blood pressure. <i>World Journal of Cardiology</i> , 2010 , 2, 125-30 | 2.1 | 1 |
| 17 | Echocardiographically defined haemodynamic categorization predicts prognosis in ambulatory heart failure patients treated with sacubitril/valsartan ESC Heart Failure, 2022, | 3.7 | 1 |
| 16 | Cardiovascular safety of the tyrosine kinase inhibitor nintedanib. <i>British Journal of Clinical Pharmacology</i> , 2021 , 87, 3690-3698 | 3.8 | 1 |
| 15 | Inflammatory Mechanisms in the Pathogenesis of Pulmonary Arterial Hypertension: Recent Advances. <i>Comprehensive Physiology</i> , 2021 , 11, 1805-1829 | 7.7 | 1 |
| 14 | New-Onset Cancer in the HF Population: Epidemiology, Pathophysiology, and Clinical Management. <i>Current Heart Failure Reports</i> , 2021 , 18, 191-199 | 2.8 | 1 |
| 13 | Oxidative stress in anticancer therapies-related cardiac dysfunction. <i>Free Radical Biology and Medicine</i> , 2021 , 169, 410-415 | 7.8 | 1 |

LIST OF PUBLICATIONS

| 12 | Essential Hypertension Worsens Left Ventricular Contractility in Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2021 , 48, 1299-1306 | 4.1 | 1 |
|----|--|--------|---|
| 11 | Anthracyclines and regional myocardial damage in breast cancer patients. A multicentre study from the Working Group on Drug Cardiotoxicity and Cardioprotection, Italian Society of Cardiology (SIC). <i>European Heart Journal Cardiovascular Imaging</i> , 2021 , 22, 406-415 | 4.1 | 1 |
| 10 | Severe Aortic Valve Regurgitation in Relapsing Polychondritis. <i>Journal of Clinical Rheumatology</i> , 2018 , 24, 109-111 | 1.1 | 1 |
| 9 | Phenotyping pulmonary hypertension in systemic sclerosis: a moving target. <i>Pulmonary Circulation</i> , 2018 , 8, 2045894018785247 | 2.7 | 1 |
| 8 | Right ventricular function as assessed by cardiac magnetic resonance imaging-derived strain parameters compared to high-fidelity micromanometer catheter measurements. <i>Pulmonary Circulation</i> , 2021 , 11, 20458940211032529 | 2.7 | 1 |
| 7 | Peripheral Vascular Function in Dilated Cardiomyopathy of Different Etiology. <i>Angiology</i> , 2020 , 71, 726- | ·723·B | 0 |
| 6 | Cardiovascular events and treatment of children with high risk medulloblastoma <i>EClinicalMedicine</i> , 2022 , 43, 101251 | 11.3 | O |
| 5 | Long-term follow-up in high risk hypertensive patients with carotid dolicoarteriopathies. <i>International Angiology</i> , 2020 , 39, 24-28 | 2.2 | O |
| 4 | Adapted recreational football small-sided games improve cardiac capacity, body composition and muscular fitness in patients with type 2 diabetes. <i>Journal of Sports Medicine and Physical Fitness</i> , 2020 , 60, 1261-1268 | 1.4 | O |
| 3 | Non-cardiovascular comorbidities in heart failure patients and their impact on prognosis. <i>Kardiologia Polska</i> , 2021 , 79, 493-502 | 0.9 | O |
| 2 | Commentary on "Functional Improvement After Outpatient Cardiac Rehabilitation in Acute Coronary Syndrome Patients is not Related to Improvement in Left Ventricular Ejection Fraction". High Blood Pressure and Cardiovascular Prevention, 2020, 27, 179-181 | 2.9 | |
| 1 | Molecular Mechanisms of Cardiovascular Damage Induced by Anti-HER-2 Therapies. <i>Current Clinical Pathology</i> , 2019 , 15-19 | 0.1 | |